Adoptive immunotherapy with ex vivo expanded tumor‐specific T cells has potential as anticancer therapy. Preferentially expressed antigen in melanoma (PRAME) is an attractive target overexpressed in several cancers including melanoma and acute myeloid leukaemia (AML), with low expression in normal tissue outside the gonads. We developed a GMP‐compliant manufacturing method for PRAME‐specific T cells from healthy donors for adoptive immunotherapy.

中文翻译：

---

使用 CD137 激活标记选择的 PRAME 抗原特异性 T 细胞的离体富集用于过继免疫治疗

体外扩增的肿瘤特异性 T 细胞的过继性免疫治疗具有抗癌治疗的潜力。黑色素瘤中优先表达的抗原 (PRAME) 是一种有吸引力的靶标，在包括黑色素瘤和急性髓性白血病 (AML) 在内的几种癌症中过度表达，在性腺外的正常组织中表达低。我们为来自健康供体的 PRAME 特异性 T 细胞开发了一种符合 GMP 的制造方法，用于过继免疫治疗。